FDA warning letter · Drugs

Maria E. De La Torre Silva, M.D.

Issued · Posted by FDA

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].

Passage 2

You failed to maintain adequate records of the disposition of the drug, including dates, quantity, and use by subjects [21 CFR 312.62(a)].

Passage 3

You failed to adhere to these requirements. Specifically, for six subjects enrolled on Protocol **(b)(4)**, the following discrepancies were observed between the quantity of drug used by the subjects and the quantity of drug returned, as recorded on the site IP accountability record; the EDC records of subjects’ self-reported doses; and the EDC records of site-reported IP returned (used and unused):

Citations in the original letter

As cited in this historical letter, not a statement of current regulatory requirements.

  • 21 CFR 312.60
  • 21 CFR 312.62(a)
  • 21 CFR 312